Collplant Holdings (CLGN) Receives a Buy from H.C. Wainwright

By Jason Carr

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Collplant Holdings (CLGNResearch Report), with a price target of $7.00. The company’s shares closed last Monday at $4.95.

According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.6% and a 35.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals, ThermoGenesis Holdings, and IntelGenx Technologies.

Currently, the analyst consensus on Collplant Holdings is a Moderate Buy with an average price target of $8.00.

See today’s analyst top recommended stocks >>

Based on Collplant Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.23 million. In comparison, last year the company had a GAAP net loss of $1.33 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.